ReviewAntibiotics (Basel, Switzerland)2025
PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Collateral sensitivity-harnessing microbial vulnerabilities as a solution to antimicrobial resistance.Molecular biology reports · 2026Review
- Mechanism-Base Pharmacokinetic-Pharmacodynamic Modeling of Cefquinome AgainstMedical sciences (Basel, Switzerland) · 2026Article
- PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM.Microbiology spectrum · 2026Observational
- Simultaneous measurement of piperacillin, tazobactam and meropenem in patient samples using LC-MS/MS to support β-lactam therapeutic drug monitoring.Analytical methods : advancing methods and applications · 2026Article
- Antimicrobial resistance in veterinary medicine: Mechanisms, regulation and control strategies.Veterinarni medicina · 2026Review
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review.Infectious diseases and therapy · 2026Review
- Cerebrospinal Pharmacokinetic and Pharmacodynamic Evaluation of Sulbactam: Dosing Considerations for Acinetobacter baumannii Meningitis in Pediatric Patients.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Inappropriate Antimicrobial Dosing in Regard to Renal Function in a Tertiary Hospital in Greece-A Single-Center Point Prevalence Study.Medicina (Kaunas, Lithuania) · 2026Article
- Reflections on the Theoretical Prerequisites for Initial Oral Antibiotic Treatment for Paediatric Bone and Joint Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open forum infectious diseases · 2026Review
- Antimicrobial pharmacokinetics and stewardship in critically Ill adult patients receiving ECMO: Challenges, evidence, and future directions.JHLT open · 2026Article
- Toward Model-Informed Precision Dosing of Imipenem: Multicenter External Validation of Population Pharmacokinetic Models in Adult Critically Ill Patients.Drug design, development and therapy · 2026Article
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- Retrospective analysis of adverse drug reaction patterns from the national monitoring system in a tertiary care hospital in China (2019-2024).Open medicine (Warsaw, Poland) · 2026Article
- Targeting Oral Pathogens withAntibiotics (Basel, Switzerland) · 2025Article
- Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2025Article
- "Dusting Off the Cobwebs": Rethinking How We Use New Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- A Paradigm Shift in SSTI Management: The Multifunctional Role of Extracellular Vesicles.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework for optimizing antimicrobial therapy, particularly to respond to evolving resistance patterns. This review examines PK/PD strategies for antimicrobial dosing optimization, focusing on three key aspects. First, we discuss the importance of drug concentration management for enhancing efficacy while preventing toxicity, considering various patient populations, including pediatric and elderly patients with their unique physiological characteristics. Second, we analyze different PK modeling approaches: the classic top-down approach exemplified by population PK analysis, the bottom-up approach represented by physiologically based PK modeling, and hybrid models combining both approaches for enhanced predictive performance. Third, we explore clinical applications, including nomogram-based dosing strategies, Bayesian estimation, and emerging artificial intelligence applications, for real-time dose optimization. Critical challenges in implementing PK/PD simulation are addressed, particularly the selection of appropriate PK models, the optimization of PK/PD indices, and considerations concerning antimicrobial concentrations at infection sites. Understanding these principles and challenges is crucial for optimizing antimicrobial therapy and combating AMR through improved dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.